[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 36868
1. Walker A: A European perspective on quality of life in old age. Eur J Ageing; 2005 Mar;2(1):2-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A European perspective on quality of life in old age.
  • This article focuses on the scientific study of quality of life in old age and summarises, on the one hand, what we know and, on the other, what further research is needed.
  • It consists of three main parts, with an extended introduction charting the recent evolution of a European perspective on ageing.
  • First of all, it emphasises the amorphous, multidimensional and complex nature of quality of life and the high level of inconsistency between scientists in their approach to this subject.
  • Secondly, the article summarises the main areas of consensus about quality of life in old age-its dynamic multifaceted nature, the combination of life course and immediate influences, the similarities and differences in the factors determining quality of life between younger and older people, the most common associations with quality of life and the likely variations between groups, and the powerful role of subjective self-assessment.
  • Thirdly, the main research priorities and gaps in knowledge are outlined, together with the key methodological issues which must be tackled if comparative, interdisciplinary research on quality of life is to develop further.
  • The main sources for the article are two European Framework Programme projects-the one a small five-country comparison and the other a large multidimensional project which, among other things, has been developing recommendations for research on quality of life in old age and included an extensive literature review on this topic.
  • The article also draws on the recently completed UK Growing Older Programme of research on extending quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Ethics. 1984 Sep;10(3):124-7 [6334159.001]
  • [Cites] Soc Sci Med. 1995 Nov;41(10):1439-46 [8560312.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1997 Dec 29;352(1363):1871-9 [9460072.001]
  • [Cites] Z Gerontol. 1987 Nov-Dec;20(6):367-76 [3326319.001]
  • [Cites] Aging Ment Health. 2002 Nov;6(4):355-71 [12425770.001]
  • [Cites] Qual Life Res. 2004 Apr;13(3):611-24 [15130025.001]
  • [Cites] Arch Intern Med. 2001 Dec 10-24;161(22):2694-700 [11732934.001]
  • [Cites] Tijdschr Gerontol Geriatr. 2003 Jun;34(3):96-103 [12866251.001]
  • [Cites] Scand J Soc Med. 1982;10(2):57-61 [7178870.001]
  • [Cites] Gerontologist. 1983 Aug;23(4):349-57 [6352420.001]
  • [Cites] Psychol Aging. 1998 Dec;13(4):531-43 [9883454.001]
  • [Cites] J Gerontol. 1961 Apr;16:134-43 [13728508.001]
  • [Cites] J Gerontol. 1978 Jan;33(1):109-25 [618959.001]
  • [Cites] Community Ment Health J. 1991 Feb;27(1):43-55 [2019098.001]
  • [Cites] Am J Public Health. 1991 Jan;81(1):63-8 [1898500.001]
  • (PMID = 28794711.001).
  • [ISSN] 1613-9372
  • [Journal-full-title] European journal of ageing
  • [ISO-abbreviation] Eur J Ageing
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Comparative research / Quality of life / Research priorities / Successful ageing / Well-being
  •  go-up   go-down


2. Trejo Amador U, Granados Cosme JA, Ortiz Hernández L, Delgado Sánchez G: [Social Differences in Proper Detection of Cervical Uterine Cancer among Employees at a University in Mexico City]. Rev Esp Salud Publica; 2005 Jun 01;79:403-414

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Diferencias sociales de la detección oportuna de cáncer cérvico uterino en las mujeres trabajadoras de una Universidad de la Ciudad de México.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28272388.001).
  • [ISSN] 2173-9110
  • [Journal-full-title] Revista espanola de salud publica
  • [ISO-abbreviation] Rev. Esp. Salud Publica
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Cervical cancer / Inequalities / Life style / Mexico / Social conditions / Socioeconomic factors / Socioeconomic level.
  •  go-up   go-down


3. Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Proto-Siqueira R, Silva-Jr WA, Falcão RP, Zago MA: miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res; 2007 Nov;40(11):1435-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia.
  • MicroRNAs (miRNAs) are a class of small endogenous RNAs that play important regulatory roles by targeting mRNAs for cleavage or translational repression. miRNAs act in diverse biological processes including development, cell growth, apoptosis, and hematopoiesis, suggesting their association with cancer.
  • We determined the miRNA expression profile of chronic and acute lymphocytic leukemias (CLL and ALL) using the TaqMan MicroRNA Assays Human Panel (Applied Biosystems).
  • Pooled leukemia samples were compared to pooled CD19+ samples from healthy individuals (calibrator) by the 2-DD Ct method.
  • One of its putative targets, SOCS1, promotes STAT activation, which is a known mediator of cell proliferation and survival, suggesting the possibility of an association between miR-331 and these processes.
  • This initial screening provided information on miRNA differentially expressed in normal and malignant B-cells that could suggest the potential roles of these miRNAs in hematopoiesis and leukemogenesis.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17934639.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


Advertisement
4. Mateo J, Abarzuza R, Núñez E, Cristóbal JA: [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission]. Arch Soc Esp Oftalmol; 2007 Mar;82(3):167-70
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission].
  • [Transliterated title] Infiltración bilateral del nervio óptico en un caso de leucemia aguda linfoblástica de células T en remisión.
  • CASE REPORT: An 18-year-old male affected by acute lymphoblastic leukemia (ALL) after having reached complete remission after chemotherapy developed bilateral optic nerve infiltration.
  • [MeSH-major] Leukemic Infiltration. Optic Nerve / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Fundus Oculi. Humans. Male. Papilledema / diagnosis. Prognosis. Recurrence. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357894.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Chang P, Kang M, Xiao A, Chang J, Feusner J, Buffler P, Wiemels J: FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia. BMC Cancer; 2010 Sep 27;10:513
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia.
  • BACKGROUND: Mutations in FLT3 result in activated tyrosine kinase activity, cell growth stimulation, and a poor prognosis among various subtypes of leukemia.
  • We evaluated the prevalence and timing of origin of FLT3 mutations in a population series of childhood leukemia patients from Northern California.
  • METHODS: We screened and sequenced FLT3 mutations (point mutations and internal tandem duplications, ITDs) among 517 childhood leukemia patients, and assessed whether these mutations occurred before or after birth using sensitive "backtracking" methods.
  • RESULTS: We determined a mutation prevalence of 9 of 73 acute myeloid leukemias (AMLs, 12%) and 9 of 441 acute lymphocytic leukemias (ALLs, 2%).
  • Among AMLs, FLT3 mutations were more common in older patients, and among ALLs, FLT3 mutations were more common in patients with high hyperdiploidy (3.7%) than those without this cytogenetic feature (1.4%).

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):578-81 [16537719.001]
  • [Cites] Blood. 2010 Oct 14;116(15):2752-8 [20592250.001]
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1091-100 [16597704.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1217-20 [16642044.001]
  • [Cites] Leuk Res. 2006 Sep;30(9):1085-9 [16533526.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):26-33 [17910045.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):64-70 [17943971.001]
  • [Cites] J Natl Cancer Inst Monogr. 2008;(39):87-90 [18648011.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6803-9 [18701506.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1692-7 [18548099.001]
  • [Cites] Radiat Prot Dosimetry. 2008;132(2):212-9 [18940823.001]
  • [Cites] Methods Mol Biol. 2009;538:7-27 [19277581.001]
  • [Cites] Drug Resist Updat. 2009 Jun;12(3):81-9 [19467916.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2722-4 [10753857.001]
  • [Cites] Blood. 2000 Jul 1;96(1):264-8 [10891460.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2992-6 [11929791.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Environ Health Perspect. 2002 Sep;110(9):955-60 [12204832.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Semin Hematol. 2002 Oct;39(4 Suppl 3):6-11 [12447846.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):36-43 [12661004.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):650-65 [12951584.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1085-8 [14504097.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Leukemia. 1996 Feb;10(2):213-24 [8637229.001]
  • [Cites] Genes Chromosomes Cancer. 1996 May;16(1):40-5 [9162196.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Leukemia. 2005 Mar;19(3):415-9 [15674422.001]
  • [Cites] Med Oncol. 2009 Dec;26(4):460-2 [19085113.001]
  • [Cites] Leukemia. 2010 May;24(5):924-31 [20237506.001]
  • [Cites] Blood Cells Mol Dis. 2010 Oct 15;45(3):186-91 [20688547.001]
  • [Cites] BMC Cancer. 2006;6:100 [16630339.001]
  • (PMID = 20875128.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089032; United States / NCI NIH HHS / CA / R01 CA089032-06; United States / NIEHS NIH HHS / ES / P42ES0470; United States / NCI NIH HHS / CA / R01 CA089032-05; United States / NCI NIH HHS / CA / R01CA89032; United States / NIEHS NIH HHS / ES / R01ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2955609
  •  go-up   go-down


6. Ansari M, St-Onge G, Krajinovic M: [Pharmacogenomics of acute lymphoblastic leukemia]. Med Sci (Paris); 2007 Nov;23(11):961-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacogenomics of acute lymphoblastic leukemia].
  • [Transliterated title] Pharmacogénétique de la leucémie lymphoblastique aiguë
  • Pharmacogenomics of acute lymphoblastic leukemia (ALL) evolved rapidly in the past few years.
  • Leukemia is the most common cancer affecting children, with ALL comprising 80 % of all leukemia cases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021708.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Von Behren J, Reynolds P, Gunier RB, Rull RP, Hertz A, Urayama KY, Kronish D, Buffler PA: Residential traffic density and childhood leukemia risk. Cancer Epidemiol Biomarkers Prev; 2008 Sep;17(9):2298-301
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential traffic density and childhood leukemia risk.
  • BACKGROUND: Exposures to carcinogenic compounds from vehicle exhaust may increase childhood leukemia risk, and the timing of this exposure may be important.
  • METHODS: We examined the association between traffic density and childhood leukemia risk for three time periods: birth, time of diagnosis, and lifetime average, based on complete residential history in a case-control study.
  • RESULTS: We included 310 cases of acute lymphocytic leukemias (ALL) and 396 controls in our analysis.
  • The odds ratio for ALL and residential traffic density above the 75th percentile, compared with subjects with zero traffic density, was 1.17 [95% confidence interval (95% CI), 0.76-1.81] for residence at diagnosis and 1.11 (95% CI, 0.70-1.78) for the residence at birth.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1091-100 [16597704.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):2920-9 [16425269.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2000 Jan-Feb;10(1):66-85 [10703849.001]
  • [Cites] Am J Epidemiol. 2001 Mar 1;153(5):433-43 [11226975.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):665-73 [12296514.001]
  • [Cites] Ann Epidemiol. 2002 Oct;12(7):482-7 [12377426.001]
  • [Cites] Environ Sci Technol. 2002 Dec 15;36(24):5405-10 [12521168.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):663-8 [12676632.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2003 May;13(3):240-6 [12743618.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):596-9 [14696126.001]
  • [Cites] Epidemiology. 2004 Jan;15(1):6-12 [14712141.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):915-21 [15128601.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):922-4; discussion 925 [15128602.001]
  • [Cites] Occup Environ Med. 2004 Sep;61(9):773-8 [15317919.001]
  • [Cites] Am J Epidemiol. 1979 Mar;109(3):273-84 [453167.001]
  • [Cites] Environ Health Perspect. 1989 Jul;82:165-9 [2477239.001]
  • [Cites] Scand J Work Environ Health. 1989 Oct;15(5):360-3 [2477895.001]
  • [Cites] Scand J Work Environ Health. 1998 Feb;24(1):8-11 [9562395.001]
  • [Cites] Cancer Invest. 2005;23(1):60-75 [15779869.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):138-45 [17366834.001]
  • (PMID = 18768496.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092674-05; United States / NCI NIH HHS / CA / R01-CA92674; United States / NIEHS NIH HHS / ES / R01-ES09137; United States / NIEHS NIH HHS / ES / R01 ES009137; United States / NCI NIH HHS / CA / R01 CA092674-05; United States / NCI NIH HHS / CA / R01 CA092674
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vehicle Emissions
  • [Other-IDs] NLM/ NIHMS93299; NLM/ PMC2706505
  •  go-up   go-down


8. Openness will benefit all. Nurs Stand; 2009 Oct 21;24(7):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Openness will benefit all.
  • : The decision to allow Margaret Haywood back onto the nursing register with only a caution against her name will prove popular with most nurses.
  • The Nursing and Midwifery Council (NMC) is to be applauded for acknowledging that the independent panel that struck her off had been too harsh.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28033801.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Gray J: Voices - Public conveniences need to be accessible to all, says Jean Gray. Nurs Stand; 2010 Aug 25;24(51):26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voices - Public conveniences need to be accessible to all, says Jean Gray.
  • : We British have traditionally been rather proud of our toilets.
  • From 19th century adventurers to package holiday travellers, millions of Britons have returned home convinced of the UK's superiority in all things lavatorial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28034038.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Anionwu E: Voices - france's public health service may not be that superior after all. Nurs Stand; 2009 Jan 28;23(21):26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voices - france's public health service may not be that superior after all.
  • : One of my new year resolutions was to improve my spoken French.
  • Ideally, I would like to go on holiday to the French West Indies and improve my vocabulary while lounging on a beach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006217.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Jones S: Fair care for all. Nurs Stand; 2005 Feb 23;19(24):22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fair care for all.
  • : The RCN wants long-term nursing care to be assessed and delivered by the nursing work-force and funded centrally by the NHS.
  • This would end the lottery in the provision of long-term care across the UK.
  • Scotland is leading the way, having agreed to fund personal care, but faces difficulties with implementation.
  • The most important thing for patients in long-term care is to have their needs assessed by a nurse.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006171.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Richards S: One jab benefits all. Nurs Stand; 2005 Mar 30;19(29):19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Next month, the Department of Health (DH) is recommending an extension of the vaccination programme against pneumococcal disease to all people aged 65 and over in England and Wales, At present, it is recommended for those aged 75 and over.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27985083.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Thomas L: Patients' nominations are the greatest compliment of all, says Linda Thomas. Nurs Stand; 2009 Sep 16;24(2):26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients' nominations are the greatest compliment of all, says Linda Thomas.
  • : Being nominated for an award by your peers is a great compliment.
  • Being nominated by patients and clients is something else again.
  • Nursing Standard is collaborating with the Patients Association again this year to run the Patient's Choice award.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28061193.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Dempsey RJ: Neurogenesis in Adults: Maybe You can Teach Old Dogs New Tricks after All! Neurosurgery; 2009 Apr 01;64(4):N12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurogenesis in Adults: Maybe You can Teach Old Dogs New Tricks after All!

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28175563.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Readers panel-free for all. Nurs Stand; 2006 Feb 22;20(24):28-29

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Readers panel-free for all.
  • : Our experts consider a hot topic of the day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27977938.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Vedam S, Docef A, Fix M, Murphy M, Keall P: Dosimetric impact of geometric errors due to respiratory motion prediction on dynamic multileaf collimator-based four-dimensional radiation delivery. Med Phys; 2005 Jun;32(6Part1):1607-1620

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosimetric impact of geometric errors due to respiratory motion prediction on dynamic multileaf collimator-based four-dimensional radiation delivery.
  • The synchronization of dynamic multileaf collimator (DMLC) response with respiratory motion is critical to ensure the accuracy of DMLC-based four dimensional (4D) radiation delivery.
  • In practice, however, a finite time delay (response time) between the acquisition of tumor position and multileaf collimator response necessitates predictive models of respiratory tumor motion to synchronize radiation delivery.
  • Predicting a complex process such as respiratory motion introduces geometric errors, which have been reported in several publications.
  • However, the dosimetric effect of such errors on 4D radiation delivery has not yet been investigated.
  • Thus, our aim in this work was to quantify the dosimetric effects of geometric error due to prediction under several different conditions.
  • Conformal and intensity modulated radiation therapy (IMRT) plans for a lung patient were generated for anterior-posterior/posterior-anterior (AP/PA) beam arrangements at 6 and 18 MV energies to provide planned dose distributions.
  • Respiratory motion data was obtained from 60 diaphragm-motion fluoroscopy recordings from five patients.
  • A linear adaptive filter was employed to predict the tumor position.
  • The geometric error of prediction was defined as the absolute difference between predicted and actual positions at each diaphragm position.
  • Distributions of geometric error of prediction were obtained for all of the respiratory motion data.
  • Planned dose distributions were then convolved with distributions for the geometric error of prediction to obtain convolved dose distributions.
  • The dosimetric effect of such geometric errors was determined as a function of several variables: response time (0-0.6 s), beam energy (6∕18MV), treatment delivery (3D∕4D), treatment type (conformal/IMRT), beam direction (AP/PA), and breathing training type (free breathing/audio instruction/visual feedback).
  • Dose difference and distance-to-agreement analysis was employed to quantify results.
  • Based on our data, the dosimetric impact of prediction (a) increased with response time, (b) was larger for 3D radiation therapy as compared with 4D radiation therapy, (c) was relatively insensitive to change in beam energy and beam direction, (d) was greater for IMRT distributions as compared with conformal distributions, (e) was smaller than the dosimetric impact of latency, and (f) was greatest for respiration motion with audio instructions, followed by visual feedback and free breathing.
  • Geometric errors of prediction that occur during 4D radiation delivery introduce dosimetric errors that are dependent on several factors, such as response time, treatment-delivery type, and beam energy.
  • Even for relatively small response times of 0.6 s into the future, dosimetric errors due to prediction could approach delivery errors when respiratory motion is not accounted for at all.
  • To reduce the dosimetric impact, better predictive models and/or shorter response times are required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28513955.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Collimation / Conformal radiation treatment / Dosimetry / Dosimetry/exposure assessment / Hemodynamics / Intensity modulated radiation therapy / Lungs / Multileaf collimators / Pneumodyamics, respiration / Pneumodynamics / Quantum dots / Radiation therapy / Radiation treatment / Real time information delivery / Wedges and compensators / adaptive filters / collimators / diagnostic radiography / dosimetry / lung / pneumodynamics / radiation therapy / tumours
  •  go-up   go-down


17. Szczepanska S, Scullion J, Holyoake DD, Brown J: Stars fall to earth. Nurs Stand; 2005 Jan 12;19(18):26-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stars fall to earth.
  • : Everyday concerns count more As an NHS employee, I must admit I could not care less about star ratings.
  • I certainly do not feel I should leave my trust to work in another one with a higher star rating.
  • I do not feel stars reflect performance accurately at all.
  • If a hospital is failing in certain areas why not just point it out and let it make changes?
  • Maybe the new grading system will be fairer, but I will wait and see.
  • As a patient due to have surgery shortly, I have no idea what star rating the hospital has.
  • And as long as I survive the surgery, am nursed in a clean ward and do not catch an infection, I do not care how the trust is rated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27985052.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Evans WE, Relling MV: Pharmacogenomics of childhood acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):s3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenomics of childhood acute lymphoblastic leukemia (ALL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962369.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Fauzdar A, Mahajan A, Jain D, Mishra M, Raina V: Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia: A case report. J Clin Oncol; 2009 May 20;27(15_suppl):e21000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia: A case report.
  • : e21000 Background: Chromosome abnormalities of leukemia cells have important prognostic significance in childhood acute lymphoblastic leukemia (ALL).
  • B-cell precursor acute lymphoblastic leukemia (BCP-ALL) ETV6/RUNX1 (alias TEL/AML1) is most frequent i.e.
  • We report two new cases with Pre B- cell ALL without ETV6/RUNX1 rearrangement, showing amplification of AML1 gene detected by FISH analysis.
  • RESULTS: In first case a 3-year girl with four copies of AML (RUNX1) gene were observed in 95% of the cell with normal two copies of TEL (ETV6) gene in both interphase and metaphase FISH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hanrahan EO, Kim F, Lin HY, Tran HT, Ryan AJ, Krebs AD, Lee JJ, Johnson BE, Heymach JV, Kim ES: Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib. J Clin Oncol; 2009 May 20;27(15_suppl):9596

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Mukhopadhyay A, Gupta P, Mukhopadhyay S, Dey S, Basak J, Pandey R: Result of adolescent acute lymphoblastic leukemia protocol (MCP 841) from a developing country. J Clin Oncol; 2009 May 20;27(15_suppl):10046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Result of adolescent acute lymphoblastic leukemia protocol (MCP 841) from a developing country.
  • : 10046 Background: Acute Lymphatic Leukemia is a curable disease in the range of 80 - 90% in developed countries by aggressive protocol like BFM, St. Judes' but result is much less in adolescence age group (60-70%).
  • In a follow-up period of 24 - 88 months (with an average of 54 months) the disease-free survival ( DFS) was 42 (56%) patients with an overall survival of 46 (61.34%) patients.
  • The major cause of the mortality was infection 18% (24.0% patients) followed progressive disease 9 (12.0%) and hemorrhage 2 (2.7%).
  • CONCLUSIONS: The data of acute lymphatic leukemia in adolescent is not satisfactory as compared to other pediatric patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962472.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Bhargava P, Esteves B, Nosov DA, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Lee P, Al-Adhami M, Ryan J: Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).
  • 53% pts were treatement naïve, 72% had undergone nephrectomy and 83% had RCC with clear cell component.
  • With a median duration of treatment of 5 mo (range 0-12 mo), the investigator assessed ORR (CR+PR) is 27.2% (30% in clear cell RCC), SD 60.5% and Disease Control Rate (CR/PR + SD) 88%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. The best job of all. Nurs Stand; 2010 Oct 13;25(6):22-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The best job of all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28029950.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Nursing care / ● Campaigns / ● Nurse champion / ● Nurses awards / ● Patient safety / ● RCN
  •  go-up   go-down


24. Te Loo DM, van Schie RM, Hoogerbrugge PM: Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukemia.
  • : 10049 Background: Vincristine is one of the corner stitches in the treatment of children with acute lymphoblastic leukemia (ALL).
  • METHODS: In total, twenty pediatric patients with de novo ALL were included in this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kiers HA: Properties of and Algorithms for Fitting Three-Way Component Models with Offset Terms. Psychometrika; 2006 Jun;71(2):231-256

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Properties of and Algorithms for Fitting Three-Way Component Models with Offset Terms.
  • Prior to a three-way component analysis of a three-way data set, it is customary to preprocess the data by centering and/or rescaling them.
  • Harshman and Lundy (1984) considered that three-way data actually consist of a three-way model part, which in fact pertains to ratio scale measurements, as well as additive "offset" terms that turn the ratio scale measurements into interval scale measurements.
  • They mentioned that such offset terms might be estimated by incorporating additional components in the model, but discarded this idea in favor of an approach to remove such terms from the model by means of centering.
  • Then estimates for the three-way component model parameters are obtained by analyzing the centered data.
  • In the present paper, the possibility of actually estimating the offset terms is taken up again.
  • First, it is mentioned in which cases such offset terms can be estimated uniquely.
  • Next, procedures are offered for estimating model parameters and offset parameters simultaneously, as well as successively (i.e., providing offset term estimates after the three-way model parameters have been estimated in the traditional way on the basis of the centered data).
  • These procedures are provided for both the CANDECOMP/PARAFAC model and the Tucker3 model extended with offset terms.
  • The successive and the simultaneous approaches for estimating model and offset parameters have been compared on the basis of simulated data.
  • It was found that both procedures perform well when the fitted model captures at least all offset terms actually underlying the data.
  • The simultaneous procedures performed slightly better than the successive procedures.
  • If fewer offset terms are fitted than there are underlying the model, the results are considerably poorer, but in these cases the successive procedures performed better than the simultaneous ones.
  • All in all, it can be concluded that the traditional approach for estimating model parameters can hardly be improved upon, and that offset terms can sufficiently well be estimated by the proposed successive approach, which is a simple extension of the traditional approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Psychol. 1992 Sep;47(9):1102-14 [1329589.001]
  • (PMID = 28197950.001).
  • [ISSN] 1860-0980
  • [Journal-full-title] Psychometrika
  • [ISO-abbreviation] Psychometrika
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; additive terms / preprocessing / three-way component models
  •  go-up   go-down


26. Lin C, Moore D, DeMichele A, Ollila D, Montgomery L, Liu M, Krontiras H, Gomez R, Esserman L, I-SPY TRIAL Investigators: Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening. J Clin Oncol; 2009 May 20;27(15_suppl):1503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening.
  • : 1503 Background: It is assumed that most locally advanced breast cancers (LABC) could be detected at an earlier stage with routine screening.
  • However, LABCs may present between screens as interval cancers (IC).
  • ICs present at an earlier age, with higher grade, larger size, and are associated with lower survival, compared to screen-detected cancers (SDC), and comprise 17% of cancers from population-based screening programs.
  • We evaluated the screening history in patients with LABCs from the I SPY TRIAL, to determine the frequency of screening and ICs.
  • METHODS: Of 221 pts enrolled in the I-SPY TRIAL, a multisite neoadjuvant study for women with LABCs > 3cm in size, screening history and presentation were retrospectively collected for 154.
  • Two groups, screened (S), defined as a mammogram within 2 years, or non screened (NS), previous mammogram more than 2 years prior, were evaluated (Table).
  • The frequency of ICs at 1 and 2 years was determined in S pts.
  • Frequency of mammographically occult (MO) tumors was determined for all.
  • RESULTS: Of the total, 99 (64%) and 55 (36%) were NS and S, respectively.
  • Mean tumor size for all pts was 6.7cm.
  • Only 11 (20%) of S pts were SDCs and 44 (80%) were ICs, with 24 (63%) diagnosed within 1 year and 14 (37%) between 1 and 2 yrs of their last normal mammogram.
  • 24 (24%) NS patients were younger than the recommended screening age of 40; in the remaining 75 pts, 9 (12%) were MO.
  • Only 20% of IC tumors were MO.
  • ICs were of higher grade (44% vs 11% grade III), and tumor size (7.0cm vs 4.4cm) than their SDC counterparts.
  • 80% of cancers detected in I SPY were NKI70 gene test poor prognosis.
  • Relationship to breast density and subtype is currently being assessed.
  • CONCLUSIONS: Women presenting with LABCs have a high likelihood (80%) of an IC.
  • This suggests that the growth rate of LABCs precludes early detection by conventional screening.
  • Understanding the biology of ICs will be important to develop better strategies for prevention and early detection.
  • [Table: see text] No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964313.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E, ITMO Study Group: A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. J Clin Oncol; 2009 May 20;27(15_suppl):5099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial.
  • Therapy continued until progression of disease or unacceptable toxicity.
  • Eligible pts had histological diagnosis of RCC, ECOG 0-2, no brain metastases, measurable disease and any Motzer's score.
  • Overall disease control rates (PR + stable disease SD) were 81 % versus 74 %.
  • CONCLUSIONS: The safety and efficacy data suggest that the association So + IL-2 is safe and feasible and, compared to So alone, improves tumour shrinkage, disease control rate and PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD).
  • Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Blay J, Penel N, Italiano A, Duffaud F, Rios M, Collard O, Bertucci F, Isambert N, Chaigneau L, Zintl P: Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program. J Clin Oncol; 2009 May 20;27(15_suppl):10574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program.
  • : 10574 Background: Between 2005 and 2008, 387 patients (pts) with advanced sarcoma failing doxorubicin were treated in a compassionate use program (ATU) of trabectedin in France using the standard 1.5mg/m2/CI 24h q21d regimen.
  • The purpose of this study was to assess the outcome of pts treated in this program.
  • METHODS: From 2005 to 2008, 87 centers (ctrs) included at least 1 pt in the ATU program.
  • Inclusion criteria were those of the EORTC trial (J Clin Oncol, 2005;23:5276), with no restriction on the previous number of lines.
  • A simple CRF with 22 items was used to collect pts characteristics and outcome.
  • One hundred eighty-nine pts files were collected as of December 20, 2008.
  • Univariate and multivariate analyses of prognostic factors was performed.
  • RESULTS: Two hundred thirty-five pts were included in the 17 ctrs in which >4 pts were treated.
  • Forty-four ctrs treated only 1 pt.
  • Fifty-two percent were female; major histological subgroups were leiomyosarcoma (29%) and liposarcoma (20%).
  • All pts had been treated with doxorubicin and ifosfamide, 3 (1.5%) in adjuvant setting only.
  • Trabectedin was given in 1st, 2nd, 3rd, or 4th line in metastatic phase in n=8, 69, 66, 42 pts respectively (median: 3rd line).
  • The median number of courses were 3 (range 1-24).
  • Best response reported were PR, n=15 (8%), SD, n=68 (36%) and PD, n=94 (50%), NE, n=11 (6%).
  • With a median follow-up of 805 days (d), median PFS and OS were 91 d and 309 d respectively.
  • 27/127 (20%) evaluable pts had to be hospitalized for treatment related side effects.
  • PFS was superior in myxoid liposarcoma (MyxLPS) (median 192 d vs 69 d, p=0.003), retroperitoneal sarcomas (median 104 d vs 69 d, p=0.006), and grade 1 tumors (median 141 d vs 70 d, p=0.01).
  • In multivariate analysis (Cox model), tumor site, grade 1, histotype were the only independent prognostic factors for PFS.
  • For OS, favorable prognostic factors in univariate analysis were histotypes (MyxLPS, MFH), grade 1 lesions, retroperitoneal site, no hospitalisation for toxicity (p<0.01 all) while Cox model identified female gender, tumor site, histotype as the only independent prognostic factors for OS.
  • CONCLUSIONS: In this compassionate use program for heavily pretreated pts with advanced sarcomas, trabectedin yielded PFS and OS close to those observed in phase II and III trial.
  • PFS and OS are superior in myxLPS, retroperitoneal sarcomas, and grade 1 tumors.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Dookeran KA, Dignam J, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S: p53 as a marker of prognosis in African American (AA) women with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 as a marker of prognosis in African American (AA) women with breast cancer.
  • : e22119 Background: Prior reports suggest that p53 may be of prognostic value in AA women with breast cancer.
  • However, it remains to be determined whether p53 status would add prognostic value beyond the commonly used factors of stage and Intrinsic Subtype Classification (subtype).
  • We evaluated p53 status as a prognostic factor among AA women treated at an urban community hospital.
  • METHODS: Cox proportional hazards regression models [results reported as hazard ratios (HR) with 95% confidence intervals (CI)] were used to select and evaluate prognostic factors [including stage, age, tumor grade of differentiation (grade), p53 status, subtype, & ER/PR status] for all-cause mortality in 331 consecutively treated AA women with breast cancer [42 months follow-up] and known subtype [luminal A = ER+, &/or PR+, & HER2-; luminal B = ER+, &/or PR+, & HER2+; HER2+ = ER-, PR-, & HER2+; basal = ER-, PR-, HER2-, cytokeratin (CK) 5/6+ &/or HER1+; & unclassified = negative for all 5 markers] and p53 [Pab1801 antibody] immunohistochemical status.
  • RESULTS: Tumors in 28% of women were p53+ and there were no chemotherapy and radiation treatment differences according to p53 status.
  • However, 59% of p53+ women were ER/PR negative [Odds Ratio (OR), 0.37; 95% CI, 0.22-0.54; p=0.0003] and hence endocrine therapy was significantly less frequent in p53+ women [OR, 0.40; 95% CI, 0.23-0.69; p=0.0008].
  • p53+ tumors were also significantly more likely to be grade 3 [OR, 4.35; CI, 1.33-14.14; p=0.013].
  • Baseline prognostic factors were: stage [(II-IV/I) HR, 2.29; 95% CI, 1.86-2.81; p<0.0001]; age [HR, 1.003 per year; 95% CI, 0.99-1.02; p=0.697]; grade [(high/low) HR, 1.70; 95% CI, 1.22-2.37; p=0.0008]; p53 status [(±) HR, 1.76; 95% CI, 1.15-2.72; p=0.012]; subtype [(all other/luminal A) HR, 1.33; 95% CI, 1.14-1.55; p=0.0004]; ER/PR status [(±) HR, 0.47; 95% CI, 0.32-0.69; p=0.0001].
  • Cox multivariable models indicated that p53 status [HR, 1.59; 95% CI, 1.01-2.51; p=0.044] remained a significant prognostic factor when considered with stage [HR, 2.20; 95% CI, 1.71-2.84; p<0.001] and subtype [HR, 1.24; 95% CI, 1.04-1.49; p=0.016] and the other above-mentioned factors.
  • CONCLUSIONS: Study results indicate that p53 status should be included with stage and subtype as markers to assess prognosis in AA women with breast cancer.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963516.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • 253 (45.8%) were AD as follows: 132 Kaposi Sarcomas, 109 aggressive B-cell lymphomas, 12 invasive cervix carcinomas.
  • The B-cell lymphomas further included 28 Burkitt's lymphomas, 30 DLBCL, 9 Castleman diseases, 8 primary cerebral lymphomas.
  • The number of pts with Hodgkin's lymphoma has increased constantly from 2000 to 2007.
  • The incidence of primary cerebral lymphomas seems to decrease, whereas the incidence of Hodgkin's lymphoma is increasing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Godoy J, Cardona AF, Cáceres H, Otero JM, Lujan M, Lopera D, Pacheco JO, Spath A, Gis P: Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e16150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study).
  • : e16150 Background: Renal cell carcinoma has increased its incidence by 126% since 1950.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963418.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Kolinsky KD, Zhang Y, Packman K, Higgins B: In vivo activity of R1530 (R) alone and in combination with docetaxel (D) and bevacizumab (B) in a prostate carcinoma (PCa) xenograft model. J Clin Oncol; 2009 May 20;27(15_suppl):e16124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its inhibitory profile includes several kinases that play critical roles in cancer cell growth and division leading to disruption at M-phase and antiangiogenic effects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Nabhan C, Tolzien K, Lestingi TM, Galvez A, Bitran JD: Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary end points included the overall clinical benefit calculated as the sum of complete response (CR), partial response (PR), and stable disease (SD), toxicity, and time to disease progression (TTP).
  • Nine pts (60%) had visceral and bone disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Bosl GJ, Motzer RJ: Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts. J Clin Oncol; 2009 May 20;27(15_suppl):5027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts.
  • METHODS: Phase I/II trial of TI-CE conducted in GCT pts with progressive disease following chemotherapy and unfavorable prognostic features (extragonadal primary site, IR to first-line therapy, or relapse/IR to ifosfamide/cisplatin-based conventional-dose salvage).
  • 5-yr disease-free survival (DFS) was 47% and overall survival 52% with a median follow-up of 61 months (m).
  • 5/21 (24%) primary mediastinal NSGCT and 2/7 late relapses are continuously disease-free.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962915.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.
  • : 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).
  • The GIP-1 randomized phase III trial (clinicaltrials.gov ID NCT00813696 ) was performed to compare the combination of cisplatin (P) and G vs. G alone as 1st-line treatment.
  • METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).
  • In arm A, G was administered at 1000 mg/m2 weekly for 7 consecutive wks, and, after a 2-week rest, on day 1, 8, 15 every 4 wks.
  • In Arm B, P 25 mg/m2 weekly (with the exception of day 22) was added to G, same dose used in Arm A (Colucci et al, Cancer 2002; 94:902-10).
  • No maximum number of cycles was planned.
  • Primary endpoint was overall survival (OS).
  • Clinical benefit (CB), objective response rate (ORR), progression-free survival (PFS), toxicity and quality of life were secondary endpoints.
  • To have 80% power of detecting a 0.74 Hazard Ratio (HR) of death (corresponding to increase in median OS from 4.8 to 6.5 months, with bilateral alpha=0.05, 400 pts were planned and 355 deaths were required for final analysis.
  • RESULTS: From April 2002 to April 2007, 400 pts were enrolled (A:199, B;.
  • 201) in 46 Italian Institutions.
  • Median age was 63 yrs (range 35-75), 59% were males, 84% stage IV, 83% KPS≥80.
  • After a median follow-up of 38.2 months and 357 deaths, median OS was 8.3 vs 7.2 months in arm A and B, respectively (HR 1.10, 95% CI 0.89-1.35, p=0.38).
  • Median PFS was 3.9 vs 3.8 months in arm A and B, respectively (HR 0.97, 95% CI 0.80-1.19, p=0.80).
  • ORR was 10.1% in arm A and 12.9% in B (p=0.37).
  • CB response was experienced by 23.0% and 15.1% (Arm A vs B, p=0.057).
  • Patients assigned to combination arm experienced more anaemia (all grades: 50% vs 39%, G3: 5% vs 1%), more neutropenia (all grades: 44% vs 36%, G3&4: 25% vs 14%) and more thrombocytopenia (all grades: 57% vs 29%, G3&4: 16% vs 5%).
  • No relevant differences were seen in non-haematological toxicity.
  • CONCLUSIONS: Weekly combination of P and G, compared to single-agent G as 1st-line treatment of APC, failed to demonstrate any improvement in OS, PFS, ORR and clinical benefit.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Stein MN, Knox B, Wesolowsky E, Levitt M, Moss R, Poplin E, Mehnert J, Gounder M, Goodin S, DiPaola R: Phase I trial of patupilone (P) and RAD001 in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In pts with prostate cancer (all previously pretreated with D) PSA declines of >50% occurred in 3/5 pts treated with >2 cycles; 1/7 pts with colon cancer had a PR and 3/7 pts with colon cancer had stable disease (SD) > 8 cycles; 1/3 pts with ampullary ca had a PR and a pt with cervical ca had SD x10 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Mishra A, Singh VP, Verma V: Environmental effects on head and neck cancer in India. J Clin Oncol; 2009 May 20;27(15_suppl):e17059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Environmental effects on head and neck cancer in India.
  • : e17059 Background: Head and neck cancer in India has unique demographic profile, environmental exposure, dietary habits, and personal and family history.
  • METHODS: 1,000 cases were analysed.
  • RESULTS: Males dominated (82%) in fifth (29%) and sixth (33%) decades.
  • Majority was uneducated (76%) and poor.
  • Passive tobacco smoking was seen in-house (85%) as well as in the work-place (80%).
  • Approximately 69% smoked more than 100 cigarettes/bidis in their lifetime.
  • Majority acquired regular smoking habit in second (73%) and third (18%) decades and continued smoking for more than 20 years (66%) with 10-20 cigarettes daily (range 1 to 43).
  • However 30% never used tobacco.
  • The main alternative forms were bidi (27%) and smokeless-tobacco chewing products (47%).
  • A past history of cancer and the subsequent radiation treatment was found in 3% while GERD in 33%.
  • Multivitamins/minerals for chemoprevention was used in 65% for 1 to 12 months.
  • Alcohol consumption was seen in 26% where the age of initiation was in second and third decade and the total years of consumption mainly varied from 10-30 years.
  • Having a predominant agriculture-based-economy, the majority of males (38%) were farmers with significant exposure to pesticides and fertilizers; while females predominantly housewifes (17%).
  • The family history was appreciated in 1% with natural parents known in all.
  • The most common sites involved were oral cavity (28%), oropharynx (30%), and larynx (32%).
  • Majority presented with advanced stage (III = 39%; IV = 23%).
  • The consumption of fruit and vegetable juice was less common as compared to fresh consumption as such.
  • Green salads, potatoes, and fiber cereals were significantly used (4-6 times a week).
  • Beans, peas, and corn was not common while beef and pork consumption rare owing .
  • The 'staple' diet was wheat, rice, pulses with additional meat mainly in Muslims (once a day).
  • The use of cooking oil, butter, eggs biscuits, cheese, cakes, and cookies was uncommon (less than once a week), but milk was abundant.
  • CONCLUSIONS: Hence, it seems that poor, education/literacy, poor socioeconomic status, tobacco smoking (passive and active) at an early age for prolonged duration, tobacco-related products and exposure to pesticides/fertilizers predispose Indian population for head and neck cancer, rather than a positive family history, dietary factors, radiation exposure, or alcoholism.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961820.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Costello BA, Hecht JR, Grothey A: Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review. J Clin Oncol; 2009 May 20;27(15_suppl):4054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review.
  • : 4054 Background: In treatment trials of patients with metastatic colorectal cancer (mCRC), KRAS mutation status of tumor samples has been retrospectively demonstrated to be predictive of treatment benefit.
  • Historically, clinical trials have not required tissue samples to be tested for KRAS mutation status as a condition of enrollment.
  • Therefore, KRAS analyses have been based on available tissue samples representing only a portion of patients retrospectively analyzed for KRAS status and correlated with treatment end- points.
  • METHODS: A weighted analysis of pooled data was performed using six recently presented or published clinical trials of targeted therapy in mCRC which tested for the association of KRAS status with Progression Free Survival (PFS).
  • The goal of the analysis was to determine whether there is a significant difference in PFS between the intention to treat (ITT) population and KRAS population in both the treatment and control arms.
  • RESULTS: The total ITT population of the pooled studies is 3864, and for the total KRAS population, 2295; a 59.4% retrieval rate (range 28-92%) for tissue samples available for KRAS analysis.
  • The weighted Δ PFS across all arms between the ITT population and the KRAS population was 0.2 months with a range of 0-0.7 months.
  • Of the 12 subgroups (6 control and 6 treatment arms), five had no difference in PFS between ITT and KRAS evaluable populations at all, and two additional subgroups demonstrated a difference PFS of only 0.1 months.
  • The two studies with the lowest tissue retrieval rates (28% and 45%) had the largest Δ PFS.
  • CONCLUSIONS: There is no meaningful difference in the PFS between the ITT and KRAS populations based on our analysis of pooled data.
  • The difference in PFS was greatest in the two studies with the lowest rate of retrieval of tissue samples for KRAS testing.
  • As such, subgroup analysis is better able to estimate and reflect the ITT population if a higher percentage of samples is able to be obtained.
  • Further, our results suggest that there is not an inherent systemic bias influencing any potentially observed differences in PFS.
  • Tissue samples should be required for all patients entering a clinical trial to avoid this issue and to make retrospective analysis more valid.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961588.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Bastos BR, Diamond J, Hansen R, Gustafson D, Arnott J, Bray M, Sidor C, Messersmith W, Shapiro G: An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following drug interruption, the pt restarted at 30 mg/m<sup>2</sup>/d and continued for 4 additional cycles before being removed for progressive disease.
  • Four ovarian cancer and 2 colon cancer pts have achieved decreases ranging from 11-61% in either CA125 or CEA, respectively (4 are associated with stable disease at Cycle 2 by modified RECIST criteria).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Besse B, Almokadem S, Planchard D, Chico I, Tsao CL, Ringeisen F, Soria J, Belani CP: Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e13513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC).
  • Partial response was seen in 6 pts and stable disease in 12 out of 18 pts who were evaluable for response by RECIST.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961304.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Dhruva NS, Stinchcombe TE, Walko CM, Socinski MA, Bernard S, Kim WY, Keller K, Hilbun LR, Dees EC: Preliminary results of a phase I trial of sorafenib combined with cisplatin/etoposide (CE) or carboplatin/pemetrexed (CbP) in solid tumor patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):e13521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13521 Background: Sorafenib had demonstrated single agent activity in non-small cell and small cell lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Ray-Coquard IL, Provençal J, Hardy-Bessard AC, Bachelot T, Coeffic D, Jacquin JP, Guastalla JP, Agostini C, Pivot X, Bajard A, Pérol D: Can adjuvant homeopathy improve the control of post-chemotherapy emesis in breast cancer patients? Results of a randomized placebo-controlled trial. J Clin Oncol; 2009 May 20;27(15_suppl):e20566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can adjuvant homeopathy improve the control of post-chemotherapy emesis in breast cancer patients? Results of a randomized placebo-controlled trial.
  • : e20566 Background: Homeopathy used as an adjunct in the treatment of chemotherapy (CT)-induced emesis has rarely been evaluated.
  • METHODS: Patients with non-metastatic breast cancer treated with 6 courses of FAC 50, FEC 100 or TAC chemotherapy were randomized to Cocculus/nux vomica/tabacum/petroleum extract (Cocculine, C) or Placebo (P) in a multicentric comparative double-blind phase III study.
  • Anti-emetic treatment was standardized (corticoids + ondansetron).
  • Patients were evaluated after each course.
  • The primary endpoint was nausea measured after the 1<sup>st</sup> CT course using the FLIE (Functional Living Index for Emesis) with 5-day recall.
  • The planned sample size was 396 evaluable patients based on a minimum expected difference in mean of 0.5 ± 1.6 on a scale from 1 (a lot) to 7 (not at all) with 5% two-sided α error and 85% power.
  • An intent-to-treat analysis was planned.
  • Secondary evaluation criteria were: vomiting measured by the FLIE score, patient self-evaluation (EVA) and investigator recording (NCI-CTC) of nausea and vomiting intensities, and compliance.
  • RESULTS: From September 05 to January 08, 431 patients were randomized (217 to P and 214 to C).
  • Patient characteristics were well balanced between groups.
  • Median age was 53 years, 35% of the patients experienced nausea or vomiting.
  • In total, 403 patients (93.5%) were assessable for the primary endpoint, with few nausea episodes (FLIE nausea scores after the 1<sup>st</sup> CT course were 6.02 and 6.07 for P and C, respectively) and very good compliance (81% patients complied with the protocol).
  • Adverse events related to nausea occurred in 51% vs. 47% of the patients treated with P and C, respectively (p = 0.48).
  • FLIE and NCI-CTC vomiting scores were similar between the 2 arms (6.91 vs. 6.88, p = 0.47, and 20% vs. 21%, p = 0.73, for P and C, respectively).
  • Grade II-III nausea occurred in 17.6% and 15.7% of patients receiving P and C (p = 0.62).
  • CONCLUSIONS: No benefit of homeopathy over standard treatment was noted in this study.
  • But surprisingly we observed lower rates of nausea and vomiting measured by patients and by investigators, than in other studies using identical chemotherapy regimens.
  • The observation and management of emesis could modify the perception and rate of such adverse events.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961132.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Spencer A, Taylor K, Lonial S, Mateos MV, Jalaluddin M, Hazell K, Bourquelot PM, San Miguel JF: Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). J Clin Oncol; 2009 May 20;27(15_suppl):8542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM).
  • : 8542 Background: Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), affecting with epigenetic and non-epigenetic pathways of cancer.
  • In vivo experiments demonstrated potent MM cytotoxicity of the triplet panobinostat + lenalidomide + dexamethasone.
  • METHODS: Trial started with 5 mg panobinostat (po, TIW) combined with fixed doses of lenalidomide (25 mg po, QD, Days 1-21) and dexamethasone (40 mg po, Days 1-4, 9-12, 17-20, Cycles 1-4), in a 28-day cycle.
  • MTD of panobinostat in this combination for second-line MM will be established based on data from cohorts of ≥6 evaluable patients (pts).
  • Safety, tolerability, PK/PD, and preliminary efficacy will be assessed.
  • RESULTS: Twenty-two pts with relapsed or relapsed refractory MM were treated in three dose levels to date.
  • Dose escalation started at 5 mg panobinostat (po, thrice weekly) combined with fixed doses of 25 mg lenalidomide (po, qd, Days 1-21) and 40 mg of dexamethasone (po, Days 1-4, 9-12, 17-20, Cycles 1-4), in a 28-day cycle.
  • Data from all eight patients in Cohort 1 were evaluated.
  • The median number of prior lines of therapy was two (range 1-3).
  • Six out of eight patients in Cohort 1 remain on therapy.
  • Median follow-up is six cycles (range 4-8+).
  • No DLT was observed.
  • In Cohort 2, eight patients were treated at the dose level of 10 mg of panobinostat, with one single DLT: a Gr 1 increase of QT interval duration was detected on Day 3, persisting on Day 8 with therapy withheld, meeting DLT definition although not deemed clinically relevant.
  • Cohort 3 is enrolling with six patients at 20 mg of panobinostat, thus far.
  • SAEs included fever (two pts), anxious depressive syndrome, respiratory infection, atrial fibrillation, exertional dyspnea, cellulitis, superficial blood clot of thigh, phlebitis, hypokalemia.
  • All, but fever in one patient, were assessed by the investigator as not study drug related.
  • CONCLUSIONS: The potential for anti-myeloma activity of this triple combination is strongly supported by in vivo preclinical data.
  • In this first clinical trial assessing this triple oral combination, the 5 and 10 mg dose level of panobinostat appear safe.
  • Updated safety, early efficacy, and subsequent dose-level patient data will be presented.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960957.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Samelis GF, Tsiakou A, Karamanidi M, Pelechrini M, Zaganides A, Ekmektzoglou K: Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival. J Clin Oncol; 2009 May 20;27(15_suppl):e15143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival.
  • Bevacizumab treatment was continuously dispensed after disease progression and only other combined drugs were altered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Evens AM, David KA, Helenowski I, Kircher SM, Mauro L, Gimelfarb A, Hattersley E, Shammo JM, Smith SE, Smith SM: Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors. J Clin Oncol; 2009 May 20;27(15_suppl):8510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors.
  • RESULTS: 81 PTLD pts were identified (SOT: 47 kidney ± pancreas, 4 pancreas, 17 liver, 8 heart, 5 lung) with median age at diagnosis (dx) of 48 yrs (range 20-72).
  • 1) PS, 2) serum albumin, 3) >1 EN site, 4) marrow involvement, 5) CNS disease and 6) RTX as part of initial therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960875.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Piura E, Chapman JW, Lipton A, Zhu L, Leitzel K, Wilson CF, Pritchard KI, Shepherd L, Pollak MN: Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. J Clin Oncol; 2009 May 20;27(15_suppl):534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrence-free survival (RFS), time from randomization to recurrence of the primary disease alone, was a secondary endpoint.
  • As expected, D levels for a population far from the equator varied with month of blood draw (p = 0.007), which gives confidence in assay performance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Piao Y, Heymach JV, Bekele B, Camphausen K, Wen PY, Liu J, Yung WK, De Groot J: Circulating cytokine and angiogenic factors as predictive biomarkers of glioblastoma response to aflibercept (VEGF Trap). J Clin Oncol; 2009 May 20;27(15_suppl):2029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Levels of 41 circulating factors were measured using suspension bead multiplex assays (BioRad) or ELISA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964597.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Balboni TA, Paulk ME, Balboni MJ, Trice ED, Wright AA, Phelps AC, Block SD, Prigerson HG: Spiritual support of patients with advanced illness and associations with end-of-life care and quality of death. J Clin Oncol; 2009 May 20;27(15_suppl):9514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Outcomes measured included medical care received in the last week of life (hospice; receipt of aggressive EoL care defined as ICU admission, resuscitation, ventilation or chemotherapy in the last week of life; and death in an acute care facility) and QoD.
  • RESULTS: In adjusted analyses, greater medical system spiritual support was associated with increased receipt of hospice care [OR = 2.97 (1.24-7.11), p = .01], but not with receipt of aggressive EoL care or death in an acute care facility.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Nguyen PL, Chen MH, Beard CJ, Loffredo M, Renshaw AA, Suh WW, Kantoff PW, D'Amico AV: Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol; 2009 May 20;27(15_suppl):5129

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Among 206 men with clinical T1b-T2b PCa and at least 1 unfavorable feature (PSA>10 or Gleason >=7 or MRI evidence of T3 disease) randomized to 70Gy of RT with or without 6 months of AST, we performed post-randomization subgroup analyses within four subgroups defined by both risk group (high risk [Gleason 8-10 or PSA >20] or intermediate risk [all others]), and by ACE-27 comorbidity level (no/limited comorbidity or moderate/severe comorbidity).
  • In men with no or minimal comorbidity, estimates of survival were significantly higher among those who received AST+RT vs. RT alone, regardless of whether they had intermediate risk disease (90.9 vs. 85.8% at 7yrs, p = 0.009) or high-risk disease (88.9% vs. 51.2% at 7yrs, p = 0.007).
  • After adjusting for known prognostic factors, treatment with RT as compared to AST+RT was associated with an increased risk of death in men with intermediate (AHR: 3.0 [95% CI: 1.3 to 7.2]; p = 0.01) and high risk disease (AHR: 3.3 [95% CI: 0.94 to 11.3]; p = 0.06) in a model that adjusted for the interaction between treatment and comorbidity.
  • CONCLUSIONS: Among men with T1b-T2b prostate cancer who have no or minimal comorbidity, the addition of 6 months of AST to RT was associated with improved survival in men with both intermediate risk and high-risk disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964400.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Schoenegg W: Capecitabine (X) in the routine treatment of advanced breast cancer (BC): Results from a large (n = 870) noninterventional study. J Clin Oncol; 2009 May 20;27(15_suppl):e12021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts were followed until disease progression or completion of 12 cycles (with long-term follow-up in pts who were progression-free after 12 cycles).
  • Generally, pts receiving X alone were slightly older and were more likely to have hormone receptor-positive disease than those receiving combination therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964311.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Holgado S, Elias de Vacaflor A, Sanchez Segura M, Viñuales A, Audi V, Raul A, Vigo G, Pedruzzi R, Zarba JJ: Risk and endocrine responsiveness (ER) categories in operated breast cancer (BC) patients (pts) from Tucuman, Argentina. J Clin Oncol; 2009 May 20;27(15_suppl):e22224

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk and endocrine responsiveness (ER) categories in operated breast cancer (BC) patients (pts) from Tucuman, Argentina.
  • : e22224 Background: BC is the most common malignancy and the 1st cause of death by cancer in women in Tucuman, Argentina.The expression of hormone receptors and Her 2 neu in tumor tissue with other microscopic variables have shown to be indicators of prognosis and is also useful in therapeutic decisions.The molecular basis for treatment selection is actually the best way for a treatment "target" identification.The objective of this trial was to determine the patients profile in the population with BC under program (all pts studied under methodologic norms of a BC Detection Program) from Tucumán Argentina, defined by risk categories (high, intermediate or low) and endocrine response (high, incomplete or no response)according St Gallen 2007.
  • METHODS: The population included in the study were 246 pts with BC from public and private institutions in the province of Tucumán.HE routine biopsies were used for the assessment of histological type and subtype, tumor grade (according to Elston et al. and Nottinghan breast cancer grading method), axillary nodes status, tumor size, and the IHC staining for estrogen, progesterone receptors and Her2 neu.The results were studied grouping and evaluating the data for risk and endocrine responsiveness.The statistic applied was the exploratory analysis.IHC methods were validated with external and internal controls, in 7 cases Her2 was determined also by Fish.
  • RESULTS: 217/246 pts completed all parameters and were classified on risk categories: high (60 patients- 27,6%-); intermediate (156 patients-71,9%-) and low (1 patient-0,5%).No significant differences were found between the ages of groups with different levels of risk.The ER of the pts(n:242/246) showed highly endocrine responsive in 109/242 (45%), incompletely endocrine responsive in 49/242 (20,2%), endocrine no responsive 84/242 (34,7%).
  • and association between endocrine levels of response and age range and tumor size (p <0001 chi-square test and p<0,017).
  • CONCLUSIONS: These results are comparable with international data and allows us to know the patients profiles in our population under BC program.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Hepp P, Rack B, Schneider A, Rezai M, Tesch H, Beck T, Söling U, Lichtenegger W, Beckmann MW, Janni W: Effects of G-CSF on circulating tumor cells (CTC) and CA 27.29 in breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):11027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cutoff for CA27.29 is 32 U/ml and >1 cell for the CTC analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963970.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Wolf SL, Qin R, Barton DL, Sloan JA, Liu H, Aaronson NK, Satele DV, Green NB, Mattar BI, Loprinzi CL: Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA. J Clin Oncol; 2009 May 20;27(15_suppl):9587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA.
  • : 9587 Background: CIPN is characterized by adjectives not covered directly by most common measures of pain and functional limitations.
  • Possible descriptors include numbness, tingling and shooting/burning pain.
  • A prospective neuropathy treatment trial provided data to explore the relationship between self-reported aspects of this symptom.
  • METHODS: Baseline EORTC QLQ CIPN20 data and NCI CTCAE V3.0 (CTC)neuropathy grade (I-IV) were provided for all patients on trial.
  • Spearman correlation coefficients and Kappa's coefficients of agreement were calculated between individual items and subscales of the CIPN20 as well as the CTC neuropathy scale.
  • Simple regression models were applied to examine the association between the sensory symptoms and motor function in the fingers/hands (F/H).
  • 200 patients provided 80% power to detect a correlation coefficient of 0.20 with a 5% Type I error.
  • RESULTS: A majority of patients reported "quite a bit" to "very much" numbness (57%) or tingling (62%) in F/H compared to "a little" or "not at all" (numbness (43%), tingling (38%)) by the CIPN20.
  • In contrast, only 13% of the participants had grade III/IV neuropathy determined by the CTC scale.
  • Fewer patients reported the higher two levels of CIPN20-measured shooting/burning pain in F/H (20% "quite a bit" to "very much").
  • Numbness and tingling were highly correlated (kappa=0.56), while neither were in high agreement with shooting/burning pain (kappa= 0.05 (tingling) and 0.14 (numbness)).
  • The CIPN20 sensory and motor subscales were significantly associated with each other (p<.0001) but were not or only weakly associated with the CTC.
  • Specifically, tingling, numbness, and shooting/burning pain were not associated with the CTC (R=0.16, 0.18 and 0 .11, respectively).
  • Using the CIPN20, all three sensations; numbness, tingling and shooting or burning pain were strongly associated with motor function.
  • CONCLUSIONS: The most common moderate to severe CIPN symptoms were numbness and tingling with shooting/burning pain being less common.
  • Shooting/ burning pain appears to be a separate symptom experience from numbness and tingling.
  • The CTC neuropathy grading scale appears to be less sensitive than the CIPN20 in picking up sensory symptoms.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963733.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Heath EI, Blumenschein GR Jr, Cohen RB, LoRusso PM, LoConte N, Kim ST, Chao R, Wilding G: Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results. J Clin Oncol; 2009 May 20;27(15_suppl):e14509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Response was evaluated for pts with measurable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Eisen T, Joensuu H, Nathan P, Harper P, Wojtukiewicz M, Nicholson S, Bahl A, Tomczak P, Wagner A, Quinn D: Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer.
  • : 5033 Background: BAY 73-4506 is an orally active, potent multikinase inhibitor targeting both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (RAF and p38MAPK).
  • METHODS: Previously untreated patients with predominantly clear cell renal cell carcinoma (RCC) and measurable disease according to RECIST were enrolled in this multicenter, open-label, phase II study.
  • Preliminary efficacy data of the 33 patients evaluable for response show a 27% partial response (PR) and a 42% stable disease (SD) rate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962938.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Cairo MS, Sposto R, Gerrard M, Waxman I, Goldman S, Auperin A, Pinkerton R, Raphael M, McCarthy K, Perkins SL, Patte C: Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial. J Clin Oncol; 2009 May 20;27(15_suppl):10032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962579.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Si L, Chi Z, Yuan X, Cui C, Sheng X, Zhu Y, Kong Y, Kong Y, Shen L, Guo J: Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab as second-line therapy for patients with stage IV acral melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible are refractory (previous one systemic regimen failed) acral advanced melanoma, measurable disease (RECIST).
  • VEGFR, PDGFR, EGFR and CD117 of tumor tissue were detected by Immunohistochemistry (IHC) assay and the DNA was abstracted and amplified by PCR assay and then sequenced to detect the mutation of C-KIT (exon11,13,17,18),B- RAF(exon11, 15) and N-RAS(exon1, 2).
  • 6 pts got stable disease (all tumor reduction, range: 4-21%) lasting > 2 cycles (range: 3-4 cycles); and 2 PD after 1 cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962568.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Mora J, Cruz O, Parareda A, Guillen A, Puy R, Massaguer S, de Torres C, Garcia G, Costa JM: Treatment of childhood glial tumors with cisplatin and irinotecan. J Clin Oncol; 2009 May 20;27(15_suppl):10062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: From January 2004 to December 2007, 30 children aged 6 months to 17 years were treated, 21 at diagnosis, 7 at progression and 2 at relapse.
  • With a median follow-up of 25 months, 14 (47%) patients had a complete/partial response (7 out of 10 HG), 10 (40%) had stable disease (8 out of 14 LG), and 6 (20%) progressed (all BST).
  • Five patients died of disease, all BST.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962497.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Nagaiah G, Fu P, Wasman JK, Cooney MM, Mooney C, Afshin D, Lavertu P, Bokar J, Savvides P, Remick SC, CTRU Research Nurses: Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol; 2009 May 20;27(15_suppl):6058

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment was continued until disease progression, unacceptable toxicity or patient refusal.
  • Two of 15 evaluable patients (13%) have partial response (PR) and 4 patients (27%) have stable disease (SD).
  • One patient died on study with rapidly progressive disease.
  • This trial is ongoing and supported in part by NIH grant nos. CA62502.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Nallapareddy S, Gustafson D, Leong S, Messersmith W, Arnott J, Eckhardt SG, Sidor C, Camidge DR: A single-center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients (pts) with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts are treated until the appearance of significant treatment-emergent toxicities or disease progression (PD) occurs.
  • 4 pts have experienced stable disease (SD) for more than 2 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Pratz KW, Cho E, Karp J, Levis M, Zhao M, Rudek M, Wright J, Smith BD: Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. J Clin Oncol; 2009 May 20;27(15_suppl):7065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias.
  • Based on preclinical activity in FLT3 mutant AML, sorafenib was studied in refractory acute leukemia.
  • METHODS: The primary objective was to determine the safety and tolerability of sorafenib in refractory acute leukemias.
  • The plasma inhibitory assay was used to measure target inhibition of phosphorylated FLT3 and phosphorylated Erk.
  • No patients met criteria for complete or partial response, but 11 of 15 (73%) patients experienced stable disease as best response, with 6 showing a reduction in bone marrow blasts after only one cycle, half of who experienced a >50% reduction in bone marrow blasts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Stone RM, Kim DW, Kantarjian HM, Rousselot P, Hochhaus A, Dorlhiac-Llacer PE, Milone J, Matloub Y, Lambert A, Shah NP: Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS). J Clin Oncol; 2009 May 20;27(15_suppl):7007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961379.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Kadia TM, Faderl S, Estrov Z, Konopleva M, George S, Lee W, Puzanov I, Chen A, Kantarjian H, Ravandi F: Final results of phase I and pharmacokinetic study of SJG-136 administered on a daily x 5 schedule. J Clin Oncol; 2009 May 20;27(15_suppl):e13506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report the results of a CTEP-sponsored phase I trial of SJG-136 administered on a daily x 5 schedule in pts with relapsed or refractory (R/R) leukemias.
  • METHODS: Previously treated pts with R/R acute leukemias (AML, ALL, high risk MDS, CML blast phase) or R/R CLL with adequate organ function and ECOG performance status of ≤ 2 were eligible for the study.
  • Thirteen (81%) pts had R/R AML, and 3 (19%) had R/R ALL of which 5 (31%) had diploid and 6 (38%) had adverse cytogenetics.
  • One pt had a PR, 8 pts had stable disease, and 6 had progression.
  • CONCLUSIONS: SJG-136 is safe and active in patients with advanced leukemias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Janelsins MC, Roscoe JA, Jean-Pierre P, Morrow GR: Cognitive functioning in breast cancer patients during and following chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e20571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive functioning in breast cancer patients during and following chemotherapy.
  • : e20571 Background: The development of cognitive difficulties, including memory loss, confusion, and difficulty concentrating following cancer treatment is a significant concern in patients receiving chemotherapy.
  • METHODS: This secondary analysis of a study assessing the effects of a RCT of paroxetine on fatigue in cancer patients investigated changes in self-report cognitive functioning over four cycles of chemotherapy and then approximately two years later.
  • Approximately half of the patients were chemotherapy naïve.
  • Questions on 5 point scales anchored by 1 = "absence of" and 5 = "a great deal" evaluating whether patients experienced heavy headedness, muddled thoughts, difficulty thinking, trouble concentrating, and forgetfulness.
  • Each was answered seven days after each treatment and scores from each cycle were summed.
  • RESULTS: Fifty-eight of 84 patients completed questionnaires for all four cycles and are included herein.
  • Paired t-tests showed cognitive difficulties were highest following the 1st on-study chemotherapy cycle (mean=7.9) and were significantly improved at the 3rd (mean=6.9) and 4th (mean=6.6) on-study cycles (both, p<0.005).
  • Independent sample t-tests revealed that paroxetine had no effect on cognitive functioning when compared to placebo at all 4 cycles (all, p>0.54).
  • Fifteen participants were reassessed two years after completing treatement.
  • There was an increase in reported cognitive difficulties from the last cycle (mean=5.9) to the follow-up time-point (mean=7.8) that was not significant (p=0.18).
  • Patients with ≥2 point change in score from the last on-study cycle to follow-up were categorized as "better" or "worse".
  • Those with <2 point change in score were classified as "no change".
  • Four (27 %) patients got worse (mean change=9.0), 2 (13 %) got better (mean change=-3.5), and 9 (60%) did not change.
  • CONCLUSIONS: These data suggest that self-report cognitive difficulties related to cancer treatment are most pronounced following initial cycles of chemotherapy treatment and improve during the treatment course.
  • Further studies need to include objective neuropsychological examinations and biological correlates of cognitive functioning to understand the extent of cognitive decline due to chemotherapy.
  • FUNDING: DOD DA17-96-C-6106, NCI R25CA10618.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV: Long-lasting responses after four doses of rituximab in Waldenström's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial. J Clin Oncol; 2009 May 20;27(15_suppl):8513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8513 Background: Waldenström's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma that is responsive to rituximab.
  • There was no difference between objective and minor responders by age, time from diagnosis to treatment in the treated group, bone marrow lymphoplasmacytes, hemoglobin level, creatinine, IgM level, or M-spike.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Gueth U, Wight E: Sequential or combination therapy in the management of recurrent ovarian carcinoma: Clinical experience beyond clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):e16530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, there are only a few reports that focus on the treatment during the entire course of disease and its changes and development over time.
  • Comparison between sub-study groups A and B showed similar overall survival (recurrent disease-specific survival): 19 months (A) vs. 18 months (B); p = 0.549.
  • The distribution of the main agents administered in the course of disease was as follows (A vs. B): carboplatin 31.0% vs. 34.7%; pegylated liposomal doxorubicin (PLD): 19.7% vs. 2.0%; gemcitabine 19.2% vs. 3.0%; paclitaxel: 10.7% vs. 14.6%; topotecan: 9.1% vs. 2.5%; others: 10.3% vs. 43.2%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960788.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong Y, Blayney DW, Niland JC, Winer EP, Weeks JC: Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). J Clin Oncol; 2009 May 20;27(15_suppl):543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN).
  • : 543 Background: Gene expression profiling has defined multiple breast cancer subtypes which can approximated using standard immunohistochemical markers.
  • METHODS: We assessed clinicopathological features and sites of recurrence for patients (pts) presenting to NCCN sites with stage I-III breast cancer from Jan 2000 to Dec 2006 where estrogen receptor (ER), progesterone receptor (PR), and HER2 status were known.
  • Tumors were grouped as luminal A (ER+ and/or PR+, and HER2-), HER2+ (any ER or PR, and HER2+), or triple-negative (ER-, PR-, and HER2-).
  • Chi-square compared proportions across tumors; univariate logistic regression estimated risk of first site of recurrence.
  • RESULTS: 12,858 pts met inclusion criteria.
  • Median follow-up from NCCN presentation was 3.2 years.
  • Subtype distribution was: triple-negative (TN) 17%; HER2+ 18%; luminal A 66%.
  • Compared to pts with luminal A and HER2+ tumors, TN were younger (p<0.0001), more likely African-American (p<0.0001) and overweight (p=0.0006).
  • TN and HER2+ tumors were less often detected by screening mammography (TN, 28.9%; HER2+, 33.6%; luminal A, 48.4%) and less likely to present as T1 (TN, 46.5%; HER2+, 50.5%; luminal A, 67.0%) or diagnosed as stage I (TN, 32.6%; HER2+ 33.2%; luminal A, 49.4%) than luminal A (all p<0.0001).
  • Rate of node positivity was lowest in TN (TN, 37.1%; HER2+, 44.9%; luminal A, 38.1%; p<0.0001).
  • 83% of TN tumors were high grade; 93% were invasive ductal histology.
  • Extensive intraductal component and lymphovascular invasion were more often associated with HER2+, compared to TN or luminal A (p<0.0001).
  • Recurrences were recorded for 1,235 pts.
  • Relative to luminal A, TN and HER2+ were more likely to experience lung (TN, odds ratio [OR] 2.27, 95% confidence interval [CI] 1.50, 3.43; p=0.0001; HER2+, OR 1.65, 95% CI 1.05, 2.60; p=0.03) and brain (TN, OR 5.32, 95% CI 2.85, 9.91; p<0.0001; HER2+, OR 5.53, 95% CI 2.93, 10.43; p<0.0001) as first site of recurrence; bone was less likely (TN, OR 0.23, 95% CI 0.16, 0.33; p<0.0001; HER2+, OR 0.38, 95% CI 0.28, 0.53; p<0.0001).
  • CONCLUSIONS: Clinicopathological features and patterns of recurrence differed significantly by subtype and may inform the design of future clinical trials.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960656.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Metges J, Gamelin E, Faroux R, Klein V, Ganem G, Douillard J, Stampfli C, Corbinais S, Riche C, Grude F: AVASTERB OUEST: A prospective cohort study of unresectable metastatic colon cancer treated successively by FOLFIRI bevacizumab and cetuximab irinotecan. J Clin Oncol; 2009 May 20;27(15_suppl):e15103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Since 2003, in west of France, (Bretagne-Pays de Loire),a network called OMIT(Observatoire des Médicaments et Innovations Thérapeutiques) directed by Regional Health Agencies has been created.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964334.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. O'Cearbhaill R, Zhou Q, Iasonos A, Soslow RA, Leitao MM Jr, Aghajanian CA, Hensley ML: Evaluation of the role of aromatase inhibitors (AIs) in the treatment of uterine leiomyosarcoma (uLMS). J Clin Oncol; 2009 May 20;27(15_suppl):5590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median age was 53 yrs (range 35-74); median body mass index 28.1 kg/m<sup>2</sup> (range 16.1-52.1); LMS grade low: 5, high: 29; hormone receptor status: 19 ER+, 9 ER-, 6 ER unknown, 9 PR+, 9 PR-, 16 PR unknown; low volume of disease (no lesion >2 cm): 19 pts(56%), high volume: 15 pts (44%).
  • Best response was partial response in 3 pts (8.8%) (all of whom were ER+), stable disease in 12 (35%), and progressive disease in 19 (56%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962398.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Langenberg MH, Witteveen PO, Lankheet N, Roodhart JM, Rosing H, Beijnen JH, Voest EE: Phase I study of combination treatment with PTK 787/ZK 222584 (PTK/ZK) and cetuximab for patients with advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and toxicity analysis. J Clin Oncol; 2009 May 20;27(15_suppl):2575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pharmacokinetics and circulating endothelial (progenitor) (CE(P)) cell analysis by flow cytometry were performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961895.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Ocvirk J, Rebersek M: Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream. J Clin Oncol; 2009 May 20;27(15_suppl):e15087

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream.
  • : e15087 Background: The EGFR-targeting monoclonal antibody cetuximab has been licensed by the EMEA in combination with chemotherapy for the treatment of 1<sup>st</sup> line metastatic colorectal cancer (mCRC) patients (pts) whose tumors have KRAS wild type status.
  • The major side effects of cetuximab are cutaneous reactions (approx.
  • 80% of pts.) predominantly consisting of an acne- like rash 60-100%, but also including pruritus, dry skin (35%), desquamation, hypertrichosis and nail disorders (10-40%).
  • If not properly managed, they have the potential to cause dose reductions and delays, which may in turn impact on treatment efficacy.
  • The aim of our study was to determine the efficacy of topical vitamin K1 cream in pts with cutaneus side effects caused by cetuximab therapy.
  • METHODS: Between January 2007 and August 2008, 79 pts with mCRC were treated with weekly cetuximab in combination with chemotherapy.
  • Topical use of a cream containing urea and 0.1% vitamin K1 was applied when an acne-like rash (NCI CTCAE version 3) appeared .
  • Pts were monitored weekly for at least 12 weeks.
  • RESULTS: Sixty nine patients developed an acne-like rash after a median of 1.2 weeks after first cetuximab administration (range 1- 4), 20 pts grade 3, 38 grade 2 and 11 grade 1.
  • Twice-daily application of vitamin K1 cream resulted in a gradual decrease in cutaneous toxicity.
  • Median time to improvement (all toxicity grades) was 1.2 weeks and 2.3 weeks to a down-staging of the rash by at least 1 grade.
  • Dose reduction of cetuximab was necessary for only 5 of the 20 pts with grade 3 toxicity.
  • No dose reductions or treatment delays were needed for any patient with grade 1 or 2 cutaneous toxicity.
  • Topical clindamycin was used concomitantly in 12/20 and 2/38 pts with grade 3 and grade 2 reactions respectively.
  • No toxicity was associated with the topical use of vitamin K1cream.
  • CONCLUSIONS: This study demonstrated the efficacy of topically applied vitamin K1 containing cream in the management of cetuximab-induced acne-like skin rash.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964556.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Breunis H, Timilshina N, Tomlinson G, Naglie G, Tannock I, Fleshner N, Krahn M, Duff Canning S, Warde P, Alibhai S: Declines in physical function from androgen deprivation therapy (ADT) in men with nonmetastatic prostate cancer: A matched cohort study. J Clin Oncol; 2009 May 20;27(15_suppl):9526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Declines in physical function from androgen deprivation therapy (ADT) in men with nonmetastatic prostate cancer: A matched cohort study.
  • : 9526 Background: Although prolonged use of ADT is hypothesized to adversely affect physical function, few studies have examined this relationship longitudinally using objective measures of physical function.
  • METHODS: Men age 50+ with non-metastatic prostate cancer (PC) starting continuous ADT were enrolled in this prospective longitudinal matched cohort study.
  • Physical function was assessed with the six-minute walk test (6MWT), grip strength, and the Timed Up and Go (TUG) test, representing endurance, upper extremity strength, and lower extremity strength, respectively.
  • Self-reported physical function was measured with the Medical Outcomes Study SF-36.
  • Assessments were done at baseline, 3 months, 6 months, and 12 months.
  • Two control groups, matched on age, education, and baseline function were also enrolled.
  • One control group had PC but did not receive ADT, and the other group did not have PC.
  • Linear mixed effects regression models were fitted adjusting for baseline covariates.
  • RESULTS: 85 patients on ADT, 86 PC controls, and 86 healthy controls were enrolled.
  • All 3 groups were similar in age (mean age 69.1 y, range 50-87) and physical function (all ANOVA p>0.05).
  • The 6MWT distance improved in both control groups (p=0.05 and 0.05 for PC and healthy controls, respectively) but remained stable in the ADT group (p=0.96)).
  • Grip strength declined in the ADT group (p=0.04), remained stable in the PC control group (p=0.31), and improved in the healthy control group (p=0.008).
  • TUG scores remained stable over time and across groups (p>0.10).
  • SF-36 physical function declined in the ADT group (p<0.001) but increased in both control groups (p<0.001).
  • Negative effects on outcomes were noted within 3-6 months of starting ADT and were larger with older age.
  • CONCLUSIONS: Endurance, upper extremity strength, and self-reported physical function are affected within 3-6 months of starting ADT, particularly in older men.
  • Declines persist at 12 months after adjustment for baseline function and covariates.
  • Exercise intervention studies to counteract these losses are warranted.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964515.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Fan L, Reeve E, Mohile S: The impact of cancer on geriatric syndromes in older Medicare beneficiaries. J Clin Oncol; 2009 May 20;27(15_suppl):9506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adjusting for possible confounders including age and comorbidity, subjects with any diagnosis of cancer were more likely to have hearing trouble (OR 1.31, 95% CI: 1.10-1.56), incontinence (OR 1.35, 95% CI: 1.16-1.57), falls (OR 1.18, 95% CI: 1.05-1.31), depression (OR 1.19, 95% CI: 1.03-1.39), and osteoporosis (OR 1.20, 95% CI: 1.06-1.35).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964461.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Heist RS, Fain J, Chinnasami B, Khan W, Molina J, Brainerd V, Leopold L, Lynch T: A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):8106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy.
  • METHODS: Pts ≥18 years of age, PS 0-1, with relapsed or refractory SCLC after first line chemotherapy with measurable disease per RECIST were eligible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964282.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Conkling P, Spigel D, McNally R, Renschler M, Oliver J: Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update. J Clin Oncol; 2009 May 20;27(15_suppl):8103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update.
  • Stable disease was achieved in 40% of pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964280.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Hofmann R: Incidence and long term prognosis of papillary renal cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and long term prognosis of papillary renal cell carcinoma.
  • : e16020 Background: Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non clear-cell kidney cancer.
  • In this study we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC).
  • RESULTS: Both groups pRCC and ccRCC were alike concerning age, body mass index, and the incidence of regional lymph node or distant metastasis at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Jotte R, Conkling P, Reynolds C, Klein L, Fitzgibbons JF, McNally R, Renschler M, Oliver JW: Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):8028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962841.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Di Fabio F, Pinto C, Rojas Llimpe F, Castellucci P, Fanti S, Mutri V, Giaquinta S, Di Tullio P, Pini S, Compagnone G, Martoni A: Early predictive value of 18F-FDG-PET assessment in advanced esophagogastric junction and gastric cancer patients treated with cetuximab-containing therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e15601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Five pts (10.2%) had FDG non- avid tumor (all pts with signet cell carcinoma).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Von Gruenigen VE, Frasure H, Fusco N, Eldermire E, Eaton S, Waggoner S: A double-blind randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin hydrochloride-related palmar-plantar erythrodysesthesia. J Clin Oncol; 2009 May 20;27(15_suppl):5594

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin hydrochloride-related palmar-plantar erythrodysesthesia.
  • : 5594 Background: To compare the efficacy of pyridoxine versus placebo in the prevention of palmar-plantar erythrodysesthesia (PPE) and on quality of life (QOL) in patients treated with pegylated liposomal doxorubicin hydrochloride for ovarian, breast, or endometrial cancer.
  • METHODS: All patients received pegylated liposomal doxorubicin hydrochloride 40 mg/m2 IV q 4 weeks over 1 hour every 28 days for a maximum of 6 cycles.
  • Patients received pyridoxine 100 mg (group A) by mouth or placebo (group B) twice daily.
  • Nurses conducted standard PPE education for all patients.
  • Patients with Grade 2 or 3 PPE that persisted despite dose reductions/delays were unblinded, and were given pyridoxine if taking placebo.
  • Patients completed the Functional Assessment of Cancer Therapy (FACT) assessment tool.
  • Analyses were conducted by group and comparisons were also made between patients who experienced grade 2/3 PPE versus grade 0/1.
  • Chi-square or Fisher's exact test were used.
  • RESULTS: Thirty-four patients were enrolled with 18 randomized to group A and 16 to group B.
  • Mean age was 64 years (SD=9.6; range 45-81 years).
  • Five patients (group A, 3; group B, 2) were unevaluable (due to pegylated liposomal doxorubicin hydrochloride reaction during first chemotherapy cycle).
  • Overall 15/29 (52%) patients had incidence of PPE (all grades), with 10/29 (34%) having grade 2/3 events (no grade 4 events observed).
  • In group A, 8/15 (53%) patients had a PPE event and 7/14 (50%) in group B; p=0.857.
  • For grade 2/3 events, there was no difference as 6/15 (40%) occurred in group A and 4/14 (29%) in group B; p=0.70.
  • There were no differences in global or domain QOL scores between those patients with Grade 2/3 PPE versus Grade 0/1.
  • Less than half [4/10 (40%)] of patients with Grade 2/3 PPE reported being bothered by side effects of pegylated liposomal doxorubicin hydrochloride treatment.
  • CONCLUSIONS: As administered in this study, pyridoxine did not prevent PPE in patients treated with pegylated liposomal doxorubicin hydrochloride.
  • Quality of life differences were not observed; however, not all patients with PPE reported being bothered by side effects of pegylated liposomal doxorubicin hydrochloride treatment.
  • Pyridoxine is not indicated for prevention of PPE during chemotherapy.
  • [Table: see text] [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Wilgenhof S, Van Nuffel AM, Benteyn D, Pierret L, Heirman C, De Coninck A, Van Riet I, Bonehill A, Thielemans K, Neyns B: Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in patients with advanced melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in patients with advanced melanoma.
  • Out of the 11 pts without evaluable disease, 2 had a local recurrence (salvaged by surgery).
  • After a mFU of 7.8 mths (range 4.3-13.7) all pts remain disease-free.
  • Out of the 13 pts with measurable disease, BOR (RECIST) was 8 SD and 5 PD; 1 pt with initial PD subsequently obtained a PR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962374.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Wagner JL, Warneke C, Bedrosian I, Mittendorf E, Babiera G, Kuerer H, Hunt K, Yang W, Sahin A, Meric-Bernstam F: Effect of modest delays in primary surgical treatment on progression of tumor size in breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):622

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: There is no evidence that time lapse from initial imaging to surgical intervention leads to significant changes in tumor size thus allowing patients to complete preoperative workup and planning without significant clinical disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961425.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Moroney JW, Coleman RL, Hong DS, Wheler JJ, Ng C, Bodurka DC, Falchook G, Naing A, Helgason T, Kurzrock R: A phase I trial of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) in advanced malignancy. J Clin Oncol; 2009 May 20;27(15_suppl):e13508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1 patient had stable disease.
  • One of the patients with endometrial cancer and extensive intra-abdominal disease who showed rapid tumor regression (≥ 25% decrease at 2 months) developed an entero-colonic fistula, and chose hospice care.
  • Patients with intra-abdominal disease who experience rapid tumor regression may be at risk for fistula formation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961272.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Onishi T, Singh V, Rosenzweig M, Sereika S, Brufsky AM: Long-term treatment with intravenous bisphosphonates in metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):1035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment with intravenous bisphosphonates in metastatic breast cancer (MBC).
  • : 1035 Background: Intravenous bisphosphonates (IV BPs) are safe and effective in reducing skeletal related events in MBC.
  • The effects of IV BPs after 24 months of therapy are unknown.
  • The incidence of osteonecrosis of the jaw (ONJ) and renal insufficiency (RI) among women with MBC receiving >= 24 months of IV BPs is also poorly defined.
  • We studied the long term effect of IV BPs in a cohort of women with MBC.
  • METHODS: We maintain an ongoing prospective database of >600 women with MBC diagnosed and treated at our institution from January 1999.
  • A long-term cohort (LTC) of 159 women with metastatic breast cancer to bone treated for >= 24 months with pamidronate (n = 9), zoledronic acid (n = 110), or both (n = 40) was identified.
  • A control cohort (CC) of 62 women with MBC to bone treated with IV BPs for 12-23 months was also identified.
  • RI was defined as an increase in serum creatinine (scr) of > 0.5 mg/dl or an absolute level of scr >1.5mg/dl; ONJ was diagnosed by dental consultation.
  • RESULTS: Median follow-up of the LTC was 39 months (range 24-99) months.
  • Median overall survival in this cohort was 43 months (range 24-114).
  • The vast majority of women in the LTC (140/159, 88.1%) continued to receive IV BPs at standard dose every 3-4 weeks.
  • The incidence of ONJ in the LTC was 6/159 (3.8%), after a mean 42.2 treatment cycles, with a median time to ONJ of 44 months.
  • Three of six patients with ONJ (50%) underwent surgical resection, and 3/6 (50%) were managed conservatively, and 3/6 (50%) resumed IV BPs after a mean 12 month hold.
  • The incidence of RI (all pts had baseline scr < 1.4 mg/dl) in the LTC was 19/159 (11.9%), occurring after a mean 43.4 treatment cycles, with a median time to RI of 43 months.
  • Eleven of 19 patients (57.9%) recovered to baseline scr and 7/19 (36.7%) patients showed partial recovery.
  • Seventeen of 19 patients (89.4%) were able to resume therapy after temporary discontinuation, decreasing the dose, or increasing the interval of the IV BP.
  • Incidence of ONJ in the CC was 1/62 (1.6%) and RI in the CC was 6/62 (9.7%).
  • CONCLUSIONS: Long term (>=24 month) IV BP use in MBC is well tolerated and safe, with relatively low incidence of ONJ and RI.
  • Most patients were able to resume IV BP therapy after a therapy hold without further complication.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961083.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Duvic M, Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y: Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. J Clin Oncol; 2009 May 20;27(15_suppl):8552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8552 Background: Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to T-cell selective intracellular accumulation of dGTP, resulting in apoptosis.
  • Six discontinued treatment (median time on treatment 440 days): 4 for progressive disease, 1 withdrew consent, and 1 due to an adverse event (Diffuse Large B-cell Lymphoma).
  • Five of 9 subjects had a response (2 with complete response, 3 with partial response, and 4 with stable disease).
  • Grade 3 or higher related AEs were experienced by 2 of 9 subjects (Diffuse Large B-Cell Lymphoma as previously mentioned and peripheral edema).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Springer B, Danoff J, Levy E, Stout N, Pfalzer L, McGarvey C, Gerber L, Soballe P: Functional recovery after surgery in patients with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During post BC treatment visits, appropriate physical therapy was provided, and if there was a diagnosis of lymphedema, a light-grade compression garment was fitted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960969.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, Stevens D, Brain E, Delaloge S, Mathieu M, Guillot E, Vincent-Salomon A, Cottu PH: Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol; 2009 May 20;27(15_suppl):517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study.
  • : 517 Background: Trials have shown benefit of adjuvant trastuzumab (TZM) for node-positive (N+) or supra-centrimetric HER-2+ breast carcinomas.
  • There are limited data concerning infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • These tumors are being recognized as a high-risk group among all T1a/b tumors.
  • METHODS: Retrospective multicenter series from 2000 to 2008 of infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • Tumors with ≥80% of ductal carcinoma in situ, multifocal and metastatic tumors were excluded.
  • RESULTS: 96 cases have been evaluated, 75 were node negative (N- InfraHER-2).
  • All patients had surgery.
  • 57% (n = 43) had a sentinel lymph node procedure.
  • 73% (n = 55) had a local irradiation and 36 a tumor bed boost.
  • Nodal irradiation of internal mammar and infra/supraclavicular regions was done in 20% and 17% respectively.
  • 44% (n = 33) had chemotherapy (CT), almost all (31) were associated to TZM.
  • Anthracycline-based (A), taxane-based (T) and A/T combinations were chosen for 54%, 4% and 42% respectively.
  • One patient developed myocardial infarction after A resulting in heart failure; 2 had a transient left ventricular ejection fraction decrease below 50% after TZM.
  • Decision of adjuvant CT was associated (all p < 0.05) with hormonal receptors (HR) negative status, Elston-Ellis grade (EE) 2/3 and high mitotic index (MI) while patients with HR+/low MI tumors were rarely treated (p < 0.001).
  • 32/39 HR+ patients received hormonotherapy (80%); 21 received aromatase inhibitors, 6 tamoxifen and 5 LHRH agonists.
  • With a 25 months median follow-up, there was no invasive recurrence in TZM treated patients.
  • 3 of the 44 patients treated without TZM nor CT (7%) had local or metastatic recurrence including one fatal; they had initially HR- EE 2/3 T1b tumors.
  • CONCLUSIONS: In our practice, decision of TZM-based therapy for InfraHER-2 N- tumors is associated with high-risk profile.
  • Indeed, N- InfraHER-2 tumors may have a significant risk of recurrence which could be avoided by adjuvant TZM.
  • Patients with N- InfraHER-2 tumors should be included in HER-2-targeted adjuvant trials.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Randall-Whitis L, Burger RA, Sill M, Monk BJ, Buening Ccrc B, Sorosky JI: Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e16505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this study was to determine the proportion of pts treated with bevacizumab on a phase II clinical trial with stable disease by RECIST who demonstrated disease progression (pgrn) as assessed by modified GCIG CA125 criteria.
  • Pts were removed from therapy/evaluation for disease prgn by RECIST, toxicity, or by subject request.
  • CONCLUSIONS: Serum CA125 levels were a useful marker of progression in some pts treated on this trial; however, some pts received clinical benefit from continued therapy in spite of indications of disease prgn by CA125.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960764.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Plunkett W, Thomas DA, O'Brien SM, Federl S, Giles FJ, Nicol SJ, Gill J, Zhao L, Ravandi F, Kantarjian H: Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia.
  • The purpose of this phase I trial was to define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of pemetrexed given with vitamin supplementation to patients with relapsed or refractory leukemia.
  • METHODS: Patients ≥15 years of age were enrolled with relapsed or refractory leukemia, Eastern Cooperative Oncology Group performance status ≤2, adequate renal and hepatic function, and life expectancy of ≥6 weeks.
  • RESULTS: Twenty-two patients entered the trial; median age was 50 years (range: 18-75); 15 patients had acute myeloid leukemia and 7 patients had acute lymphocytic leukemia (ALL).
  • Two patients died during the study due to disease progression and 1 patient discontinued due to a subdural hematoma of unknown cause.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Yeh C, Ma W, Kantarjian H, Zhang ZJ, Cortes J, Albitar M: BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):7028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7028 Background: The major mechanism underlying imatinib resistance in patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with point mutations in the BCR-ABL tyrosine kinase.
  • We describe three novel ABL premature termination mutations leading to BCR-ABL truncation in leukemia patients with multidrug (imatinib/nilotinib/dasatinib) resistance.
  • HL60 cells (a Ph-negative myeloid leukemia cell line) and peripheral blood of healthy subjects were used as negative controls; a human CML cell line (K562) was used as a positive control.
  • RESULTS: We identified an exon 7 deletion in three CML patients, a 4-nt insertion (908insCAGG) near the exon 5/6 junction in one CML case, and an exon 6 point mutation (997C>T) in one patient with acute lymphoblastic leukemia (ALL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Sharma H, Campbell AC, Thajam S, Singh BJ: Metal-on-metal surface hip arthroplasty in patients with abnormal Coxanatomy: preliminary results. Eur J Orthop Surg Traumatol; 2006 Jun;16(2):135-139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Arthroplastie de resurfaçage métal/métal en cas d’anatomie de hanche anormale.
  • These patients were defined to have abnormal coxanatomy by virtue of previous dysplastic disease of hip in three cases, previous Legg-Calve-Perthes disease, multiple epiphyseal dysplasia, T cell acute lymphoblastic leukaemia, trauma and sepsis in one case each.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Arthroplasty. 2001 Dec;16(8 Suppl 1):134-9 [11742465.001]
  • [Cites] Clin Orthop Relat Res. 1996 Aug;(329 Suppl):S89-98 [8769326.001]
  • [Cites] Clin Orthop Relat Res. 1996 Aug;(329 Suppl):S78-88 [8769325.001]
  • [Cites] Instr Course Lect. 1981;30:444-54 [6820656.001]
  • [Cites] Hip Int. 2002 Apr-Jun;12 (2):158-162 [28124361.001]
  • [Cites] Hip. 1982;:156-66 [7166497.001]
  • [Cites] Clin Orthop Relat Res. 1996 Aug;(329 Suppl):S106-14 [8769328.001]
  • (PMID = 28755114.001).
  • [ISSN] 1633-8065
  • [Journal-full-title] European journal of orthopaedic surgery & traumatology : orthopedie traumatologie
  • [ISO-abbreviation] Eur J Orthop Surg Traumatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Keywords] NOTNLM ; Anatomy / Arthroplasty / Hip / Metal-on-metal
  •  go-up   go-down


92. Khattab TM, Jastaniah WA, Felimban SK, Elemam N, Abdullah K, Ahmed B: How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia. J Clin Oncol; 2009 May 20;27(15_suppl):10048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia.
  • : 10048 Background: T-cell acute lymphoblastic leukemia (T-ALL) is representing 10-15% of pediatric ALL.
  • Our published data showed that T-ALL phenotype patients fared poorly with 5 year survival of 27% versus 83% for precursor B-ALL (Recent Advances Research Update: 2006, 7; 1, P 51-56).
  • METHODS: Retrospective review of all patients files diagnosed with T-ALL from 1989 until now with data collection including; sex, age, white cell count (WBCs), CNS disease, type of protocol used, length of survival, overall survival, cause of death (toxic, disease).
  • Median WBCs 50,000/Cmm (range: 1.500-619,000/Cmm) and positive CNS at diagnosis 10/52 (20%).
  • Overall survival 27/52 (52%) and 25 pts. died (48%); 15 secondary to disease recurrence (9 on UKALL, 4 BFM, 2 CCG 1961); 4 during induction, 1 fulminant hepatic failure, 1 tumor lysis syndrome, and 4 due to toxicities (mucormycosis, staphylococcal toxic shock syndrome, CMV pneumonia, pseudomonas sepsis).
  • Further risk and response stratification in addition to intensification of therapy for T-cell ALL in our center may prove to be beneficial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Maternal alcohol intake linked to leukaemia in childhood. Nurs Stand; 2007 Aug 29;21(51):17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal alcohol intake linked to leukaemia in childhood.
  • : More than one alcoholic drink a day during pregnancy might be associated with the development of acute lymphoblastic leukaemia in the subsequent child.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001545.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Bates J: Warts and all. Nurs Stand; 2009 Jun 10;23(40):25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Warts and all.
  • : In the NHS we encourage patients to take ownership of their health.
  • Eating and drinking sensibly, giving up smoking… the list goes on.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27996667.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Thomas L: Voices - nursing standard's nurse awards 2009 are all about you and your colleagues. Nurs Stand; 2009 Apr 02;23(30):24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voices - nursing standard's nurse awards 2009 are all about you and your colleagues.
  • : Forget the recession.
  • Put doom and gloom out of your mind.
  • Now is your chance to celebrate all that is good about nursing.
  • The closing date for entries to the Nursing Standard Nurse Awards 2009 is approaching and we want you to tell us about your achievements or the success of a talented colleague.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001986.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Brisbourne M: We should be grateful to get any student bursary at all. Nurs Stand; 2005 May 25;19(37):38-39

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] We should be grateful to get any student bursary at all.
  • : I am a third-year nursing student due to qualify in September and was interested to read another student's views on our bursary (letters May 11).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991280.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Liu H, Sloan JA, Sargent DJ, Satele DV, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Buckner JC: Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients. J Clin Oncol; 2009 May 20;27(15_suppl):9563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients.
  • : 9563 Background: Fatigue is a prevalent and debilitating symptom reported by cancer patients (pts) which compromises a pt's quality of life (QOL).
  • This study examined the relationship between PR fatigue and QOL as well as cancer-related symptoms (CRS) in 43 North Central Cancer Treatment Group and Mayo Clinic Cancer Center clinical trials.
  • METHODS: 3,915 pts from 43 oncology clinical trials provided baseline fatigue data on a single-item 0-100 point scale.
  • Pts' QOL assessment included a single-item overall QOL and associated QOL domains measured by numerical analogues, the Profile of Mood States (POMS), and PR symptom assessment measures.
  • Associations between fatigue and QOL domains were assessed by Spearman correlation coefficients.
  • Wilcoxon rank sum test compared QOL scores between pts with clinically deficient fatigue(CDF, score ≤50) vs. no clinically deficient fatigue (nCDF, score>50).
  • Changes from baseline in fatigue and QOL were compared by Wilcoxon rank sum test with a 20-point change defined as clinically meaningful.
  • RESULTS: 38% of pts reported CDF at baseline and 45% of pts reported CDF at last assessment.
  • Fatigue was only moderately correlated at best with overall QOL, pain, POMS, social and physical function (Spearman rho's of .27,.40, .56, .38 and .38 respectively).
  • Pts with CDF averaged over 10 points lower overall QOL, pain, POMS, social, and physical function (see table below, all p<.0001) as well as worsening CRS including sleepiness, nausea, headache, abnormal sweating, trouble sleeping, dry mouth, and sexual dysfunction (all p<.001).
  • Pts with 20+ points worsening in fatigue declined in overall QOL, physical function, pain and POMS (all p<.0001).
  • CONCLUSIONS: Patients with CDF suffer greater deficits in QOL and CRS.
  • Patients report fatigue as distinctly different from overall QOL, pain, physical, social, mood status and CRS.
  • Fatigue appears with a broad spectrum of CRS clusters.
  • Routine measurement and management of fatigue could impact QOL and treatment-related symptoms.
  • [Table: see text] No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Crino L, Mezger J, Griesinger F, Zhou C, Reck MM: MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • METHODS: Primary endpoint was safety; secondary endpoints included time to disease progression (TTP) and overall survival (OS).
  • Pts with untreated locally advanced, metastatic or recurrent non-squamous NSCLC (ECOG PS 0-2) received Bv (7.5 or 15mg/kg) with standard chemotherapy for up to six cycles, then non-progressors proceeded to receive Bv until disease progression.
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Orav EJ, Colan SD: Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia.
  • Adding dexrazoxane (DZR) to DOX treatment resulted in reduced myocardial injury in children with acute lymphoblastic leukemia (ALL) during Dana-Farber Cancer Institute Protocol 95-01.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962530.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. The cruellest cuts of all. Nurs Stand; 2009 Jul 07;23(44):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cruellest cuts of all.
  • Gill Donovan and Michele Pengelly are special nurses whose work is highly valued by their patients.
  • Ms Donovan set up a round-the-clock telephone callback system to give cancer patients support, advice and guidance.
  • One of her patients, Sheila Bevins, says the nurse's help was invaluable in her successful battle with breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28076083.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement